阿昔洛韦治疗传染性单核细胞增多症对发热及住院时间的影响  

Acyclovir on Fever and Hospitalization Stay in Children with Infectious Mononucleosis

作　　者：周高枫[1] 张锐沐 李迟 陈佳[1] 田树凤[1] 邓继岿[1] 

机构地区：[1]广东省深圳市儿童医院,广东深圳518038

出　　处：《儿科药学杂志》2018年第2期15-17,共3页Journal of Pediatric Pharmacy

摘　　要：目的:观察阿昔洛韦抗病毒治疗对传染性单核细胞增多症(IM)患儿发热持续时间、住院时间的影响。方法:采用回顾性研究方法,选择我院2016年收治的IM患儿100例,根据是否使用阿昔洛韦治疗分为观察组和对照组各50例,对两组患儿的发热持续时间及住院时间进行比较分析。结果:100例患儿均有发热(发热峰值38.1~41.0℃)、扁桃体肿大、浅表淋巴结肿大表现,血清EB-VCA-Ig M均阳性,血浆/血液EBV-DNA均阳性。两组患儿发热持续时间比较差异无统计学意义(P>0.05),但观察组患儿住院时间长于对照组(P<0.05)。出院时,两组患儿临床症状皆缓解,体温恢复正常,均未发生不良反应,好转或痊愈出院。结论:IM患儿在应用阿昔洛韦抗病毒治疗后,在发热持续时间及住院时间上皆无获益。Objective：To observe the effect of acyclovir in fever time and hospitalization stay in children with infectious mononucleosis.Methods：A retrospective analysis of 100 children with infectious mononucleosis in 2016 from Shenzhen Children＇s Hospital was implemented.Statistical analysis was used to compare the fever time and hospitalization stay between the acyclovir group（50 cases） and the control group（50 cases）.Results：One hundred children were fever（heat peak 38.1-41.0 ℃）,tonsil swelling,superficial lymph node enlargement.The serum EB-VCA-Ig M were positive,the plasma/blood EBV-DNA were positive.There was no significant difference in fever time between the two groups（P〈0.05）,but the hospitalization stay in the observation group was longer than the control group（P〈0.05）.At discharge time,the clinical symptoms of both groups were relieved and the temperature were returned to normal.No adverse reaction occurred.Conclusion：With regard to fever time and hospitalization stay,children with infectious mononucleosis cannot benefit from acyclovir treatment.

关 键 词：传染性单核细胞增多症 发热 住院时间 阿昔洛韦 儿童 

分 类 号：R725.1[医药卫生—儿科]